Policy Brief (Issue 3): Health Technology Assessment on Sildenafil as Treatment for Pulmonary Arterial Hypertension (PAH)

Sildenafil is a treatment option for PAH patients that is found to offer an additional 1-3 life years gained for PAH patients compared to beraprost, currently the only treatment available in the benefit package under the National Social Health Insurance (Jaminan Kasehatan Nasional – JKN) of Indonesia. Off-label use of sildenafil for treatment of PAH is recommended to be included in the benefit package. The study results indicate that there is a need for the Ministry of Health in Indonesia to consider the use of off-label medicines in the benefit package given the strong Health Technology Assessment evidence showing the drug’s benefit to the Indonesian population.

For more details of the project http://www.globalhitap.net/projects/idsi-indonesia/